Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Multiple Myeloma through trial conditions or approval indications mapped to it or to one of its descendant entities.
6 drugs · 36 active trials
25 drugs · 1,009 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dexamethasone | Approved | Phase 4 | 212 | 85 | 143 | 676 | 2 | EU, US | Mar 16, 2016 | 1994-01 |
| Lenalidomide | Approved | Phase 4 | 131 | 47 | 87 | 373 | 1 | US | Dec 27, 2005 | Apr 1, 2002 |
| Daratumumab | Approved | Phase 4 | 112 | 44 | 53 | 198 | 1 | US | Nov 16, 2015 | Jan 31, 2012 |
| Bortezomib | Approved | Phase 4 | 87 | 30 | 87 | 353 | 4 | US | May 13, 2003 | Feb 8, 2001 |
| Pomalidomide | Approved | Phase 4 | 77 | 32 | 41 | 179 | 7 | EU, US | Feb 8, 2013 | 2008-06 |
| Carfilzomib | Approved | Phase 4 | 66 | 20 | 26 | 157 | 2 | EU, US | Jul 20, 2012 | 2005-09 |
| Cyclophosphamide | Approved | Phase 4 | 46 | 22 | 26 | 223 | 1 | US | Sep 12, 2023 | 1988-03 |
| Isatuximab | Approved | Phase 3 | 42 | 17 | 12 | 54 | 2 | EU, US | Mar 2, 2020 | Jan 21, 2015 |
| Belantamab Mafodotin | Approved | Phase 3 | 38 | 12 | 9 | 55 | 3 | EU, US | Jul 23, 2025 | Jul 29, 2014 |
| Teclistamab | Approved | Phase 4 | 38 | 22 | 11 | 40 | 2 | EU, US | Aug 23, 2022 | Aug 9, 2019 |
| Elranatamab | Approved | Phase 4 | 33 | 25 | 5 | 36 | 2 | EU, US | Aug 14, 2023 | Aug 9, 2019 |
| Talquetamab | Approved | Phase 3 | 26 | 16 | 5 | 29 | 2 | EU, US | Aug 9, 2023 | Dec 13, 2018 |
| Melphalan | Approved | Phase 4 | 21 | 7 | 23 | 170 | 4 | US | Jun 9, 2009 | 1994-01 |
| Selinexor | Approved | Phase 3 | 21 | 11 | 6 | 39 | 3 | EU, US | Jul 3, 2019 | Jun 12, 2014 |
| Elotuzumab | Approved | Phase 3 | 18 | 6 | 13 | 54 | 5 | EU, US | Nov 30, 2015 | 2006-12 |
| Linvoseltamab | Approved | Phase 3 | 14 | 11 | 4 | 15 | 1 | EU | Apr 23, 2025 | Jan 23, 2019 |
| Ixazomib | Approved | Phase 4 | 11 | 3 | 7 | 69 | 2 | EU, US | Nov 20, 2015 | 2009-10 |
| Thalidomide | Approved | Phase 4 | 5 | 0 | 28 | 80 | 3 | EU, US | Jul 16, 1998 | 1998-02 |
| Ciltacabtagene Autoleucel | Approved | Phase 2 | 5 | 3 | 0 | 6 | 1 | EU | May 25, 2022 | Jun 29, 2018 |
| Plerixafor | Approved | Phase 3 | 2 | 2 | 2 | 26 | 1 | US | Dec 15, 2008 | 2004-05 |
| Idecabtagene Vicleucel | Approved | Phase 3 | 2 | 0 | 2 | 9 | 1 | EU | Aug 18, 2021 | Dec 22, 2015 |
| Doxorubicin | Approved | Phase 4 | 1 | 1 | 5 | 21 | 1 | US | Nov 17, 1995 | 1994-01 |
| Denosumab | Approved | Phase 3 | 1 | 0 | 2 | 6 | 2 | US | Aug 29, 2025 | 2005-11 |
| Panobinostat | Approved | Phase 3 | 0 | 0 | 1 | 28 | 1 | EU | Aug 28, 2015 | Mar 1, 2003 |
| Melphalan Flufenamide | Approved | Phase 3 | 0 | 0 | 2 | 5 | 1 | EU | Aug 17, 2022 | Dec 28, 2016 |
| Fludarabine | Phase 4 | Phase 4 | 25 | 11 | 10 | 151 | 0 | — | — | 1999-07 |
| Dasatinib | Phase 4 | Phase 4 | 4 | 2 | 0 | 10 | 0 | — | — | 2008-02 |
| Busulfan | Phase 4 | Phase 4 | 3 | 1 | 3 | 40 | 0 | — | — | 1988-03 |
| Prednisone | Phase 4 | Phase 4 | 3 | 0 | 10 | 32 | 0 | — | — | 1994-01 |
| Chemotherapy | Phase 4 | Phase 4 | 1 | 0 | 0 | 3 | 0 | — | — | 1997-09 |
| Zoledronic Acid | Phase 4 | Phase 4 | 0 | 0 | 4 | 19 | 0 | — | — | 1998-12 |
| Venetoclax | Phase 3 | Phase 3 | 10 | 4 | 3 | 25 | 0 | — | — | Oct 10, 2012 |
| Trametinib | Phase 3 | Phase 3 | 8 | 2 | 1 | 11 | 0 | — | — | Oct 30, 2013 |
| Etoposide | Phase 3 | Phase 3 | 7 | 3 | 6 | 29 | 0 | — | — | 1998-06 |
| Cisplatin | Phase 3 | Phase 3 | 5 | 1 | 4 | 14 | 0 | — | — | 1998-06 |
| Pembrolizumab | Phase 3 | Phase 3 | 4 | 2 | 2 | 26 | 0 | — | — | Nov 22, 2013 |
| Sirolimus | Phase 3 | Phase 3 | 4 | 2 | 1 | 22 | 0 | — | — | 2004-11 |
| Dabrafenib | Phase 3 | Phase 3 | 4 | 1 | 1 | 5 | 0 | — | — | Aug 17, 2015 |
| Nivolumab | Phase 3 | Phase 3 | 3 | 1 | 1 | 23 | 0 | — | — | Aug 2, 2012 |
| Pegfilgrastim | Phase 3 | Phase 3 | 2 | 1 | 2 | 6 | 0 | — | — | 2003-12 |
| Filgrastim | Phase 3 | Phase 3 | 1 | 0 | 5 | 50 | 0 | — | — | 1998-08 |
| Methotrexate | Phase 3 | Phase 3 | 1 | 0 | 1 | 15 | 0 | — | — | 1988-03 |
| Cytarabine | Phase 3 | Phase 3 | 1 | 1 | 2 | 8 | 0 | — | — | 1998-08 |
| Aspirin | Phase 3 | Phase 3 | 1 | 0 | 3 | 7 | 0 | — | — | 2007-01 |
| Cobimetinib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Nov 13, 2017 |
| Vemurafenib | Phase 3 | Phase 3 | 1 | 1 | 1 | 3 | 0 | — | — | Apr 12, 2012 |
| Bendamustine | Phase 3 | Phase 3 | 0 | 0 | 1 | 29 | 0 | — | — | 2008-02 |
| Vorinostat | Phase 3 | Phase 3 | 0 | 0 | 1 | 14 | 0 | — | — | 2005-09 |
| Carmustine | Phase 3 | Phase 3 | 0 | 0 | 3 | 11 | 0 | — | — | 1994-01 |
| Vincristine | Phase 3 | Phase 3 | 0 | 0 | 4 | 8 | 0 | — | — | 1994-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.